Premium
Orbital floor triamcinolone acetonide in the treatment of pseudophakic cystoid macular oedema
Author(s) -
SULEMAN H,
MATHEW M,
LAKSHMANAN A,
ABEDIN A,
ORR GM
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.6417.x
Subject(s) - medicine , triamcinolone acetonide , ophthalmology , visual acuity , perforation , maculopathy , refractory (planetary science) , acetonide , surgery , retinopathy , diabetes mellitus , materials science , physics , astrobiology , metallurgy , punching , endocrinology
Purpose To report the outcome of orbital floor triamcinolone acetonide (OFTA) in refractory pseudophakic cystoid macular oedema(PCMO) and to determine the visual outcome in these patients Methods Six eyes of 6 patients with PCMO inadequately responsive to treatment combinations of topical steroidal and non‐steroidal agents were retrospectively studied. All received 40mg (1ml) OFTA injection. Post‐operative Visual acuity (VA), intraocular pressure (IOP) and OCT findings were assessed. Other potential complications were looked for retrospectively. Results The average age was 72 years(+/‐12 years). OFTA was given, on average, 4 weeks after a diagnosis of PCMO was made (range 0‐6 weeks) and treated with topical anti‐inflammatory agent combinations. The mean follow‐up was 11.0 months (range, 5‐18), and the mean improvement of VA after OFTA was Snellen, (6/18‐6/12). This was noticed at a mean of 12 weeks (range 4‐72). At last follow‐up, five eyes showed an improvement of two lines or more, while in one eye vision was maintained at 6/24 which developed diabetic maculopathy and required grid laser. None of the patients developed post‐treatment raised IOP or lost vision. There was a significant reduction of retinal thickness and cystoid space height (P = 0.003). The dosage of topical steroids was reduced or stopped altogether in all 6 eyes. There were no cases of injection‐related retrobulbar haemorrhage, cellulitis, or globe perforation Conclusion In cases of psuedophakic CMO, initial response to OFTA treatment was encouraging. Further larger long term studies are required to ascertain whether re‐treatment is effective with subsequent orbital floor steroid injections. This is with a view to maintain the initial improvement.